PDX models indicate that dual inhibition of BRAF and FAK inhibits ERK/MAPK re-activation in the tumor stroma, which facilitates the efficient therapeutic control of BRAF-mutant melanoma [51, 139]. The gene discussed is PTK2; the disease is melanoma.